Monoclonal antibodies and other targeted therapies for pancreatic cancer

Cancer Journal (United States)

Volumn 18, Issue 6, 2012, Pages 653-664

  Cinar, Pelin ^a   Tempero, Margaret A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

monoclonal antibodies; novel therapy; Pancreatic cancer; signaling pathways; targeted therapy

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 (3 FLUOROPHENYL) N (3 PIPERIDINYL) 3 UREIDO 2 THIOPHENECARBOXAMIDE; AFLIBERCEPT; APRICOXIB; AXITINIB; BEVACIZUMAB; CAPECITABINE; CELECOXIB; CETUXIMAB; CISPLATIN; CONATUMUMAB; ERLOTINIB; FLUOROURACIL; GANITUMAB; GEMCITABINE; IRINOTECAN; MARIMASTAT; MK 0752; MONOCLONAL ANTIBODY; NVP AEW 541; OXALIPLATIN; PACLITAXEL; PD 321852; PLACEBO; RDEA 119; SALIRASIB; SELUMETINIB; SORAFENIB; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTHRALGIA; AUTOPHOSPHORYLATION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL COMPARTMENTALIZATION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMORADIOTHERAPY; CHEMOSENSITIZATION; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; IN VITRO STUDY; LIVER METASTASIS; LYMPH NODE METASTASIS; MACROPHAGE; MESENCHYMAL STEM CELL; MOLECULARLY TARGETED THERAPY; MUSCULOSKELETAL STIFFNESS; NONHUMAN; ONCOGENE H RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; MOLECULAR TARGETED THERAPY; PANCREATIC NEOPLASMS;

EID: 84871211965     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182758985     Document Type: Review

References (166)

1. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15:2403-2413.
2. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gem-citabine for metastatic pancreatic cancer. N Engl J Med. 2011;364: 1817-1825.
3. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-1617.
4. Matthaios D, Zarogoulidis P, Balgouranidou I, et al. Molecular patho-genesis of pancreatic cancer and clinical perspectives. Oncology. 2011; 81:259-272.
5. Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol. 2009;6: 412-422.
6. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
7. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806.
8. Von Hoff DD, et al. Actionable targets in pancreatic cancer detected by immunohistochemistry (IHC), microarray (MA) fluorescent in situ hybridization (FISH), and mutational analysis. J Clin Oncol. 2012; 30(suppl).
9. McCleary-Wheeler AL, McWilliams R, Fernandez-Zapico ME. Aberrant signaling pathways in pancreatic cancer: a two compartment view. Mol Carcinog. 2012;51:25-39.
10. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969-2972.
11. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239-252.
12. Chiodoni C, Colombo MP, Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev. 2010;29:295-307.
13. Kleeff J, Beckhove P, Esposito I, et al. Pancreatic cancer microenviron-ment. Int J Cancer. 2007;121:699-705.
14. Lin EY, Li JF, Gnatovskiy L, et al. Macrophages regulate the angio-genic switch in a mouse model of breast cancer. Cancer Res. 2006; 66:11238-11246.
15. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-323.
16. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol. 2008;26:2806-2812.
17. Danovi SA, Wong HH, Lemoine NR. Targeted therapies for pancreatic cancer. Br Med Bull. 2008;87:97-130.
18. Hruban RH, van Mansfeld AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas: a study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 1993;143:545-554.
19. Lohr M, Kloppel G, Maisonneuve P, et al. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neo-plasia. 2005;7:17-23.
20. Gysin S, Salt M, Young A, et al. Therapeutic strategies for targeting ras proteins. Genes Cancer. 2011;2:359-372.
21. Song SY, Meszoely IM, Coffey RJ, et al. K-rasYindependent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells. Neoplasia. 2000;2:261-272.
22. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001;61:131-137.
23. Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000;18:927-941.
24. Crul M, de Klerk GJ, Swart M, et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2002;20: 2726-2735.
25. Patnaik A, et al. A phase I and pharmacokinetic (Pk) study of the far-nesyltransferase inhibitor, R115777 in combination with gemcitabine (Gem). Proc Am Soc Clin Oncol. 2000;19.
26. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gem-citabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-1438.
27. Macdonald JS, McCoy S, Whitehead RP, et al. A phase II study of far-nesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs. 2005;23: 485-487.
28. Weisz B, Giehl K, Gana-Weisz M, et al. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene. 1999;18:2579-2588.
29. Gana-Weisz M, Halaschek-Wiener J, Jansen B, et al. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res. 2002;8:555-565.
30. Goldberg L, Kloog Y. A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinaseYdependent glioblas-toma cell migration. Cancer Res. 2006;66:11709-11717.
31. Blum R, Jacob-Hirsch J, Amariglio N, et al. Ras inhibition in glioblas-toma down-regulates hypoxia-inducible factor-1alpha, causing glycol-ysis shutdown and cell death. Cancer Res. 2005;65:999-1006.
32. Laheru D, Shah P, Rajeshkumar NV, et al. Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer [published online ahead of print]. Invest New Drugs. 2012.
33. Whyte DB, Kirschmeier P, Hockenberry TN, et al. K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997;272:14459-14464.
34. Cox AD, Hisaka MM, Buss JE, et al. Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein. Mol Cell Biol. 1992;12:2606-2615.
35. Sjogren AK, Andersson KM, Khan O, et al. Inactivating GGTase-I reduces disease phenotypes in a mouse model of K-RASYinduced myelo-proliferative disease. Leukemia. 2011;25:186-189.
36. Liu M, Sjogren AK, Karlsson C, et al. Targeting the protein prenyltrans-ferases efficiently reduces tumor development in mice with K-ras-induced lung cancer. Proc Natl Acad Sci USA. 2010;107:6471-6476.
37. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263-1284.
38. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999;18:813-822.
39. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006; 24:21-44.
40. Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13:1576-1583.
41. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26:2139-2146.
42. Bodoky G, Timcheva C, Spigel DR, et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs. 2012;30:1216-1223.
43. Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol. 2003;30:105-116.
44. Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacody-namic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005;23:5281-5293.
45. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced nonYsmall-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22: 4456-4462.
46. Diep CH, Munoz RM, Choudhary A, et al. Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res. 2011;17:2744-2756.
47. Barton CM, Hall PA, Hughes CM, et al. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol. 1991;163:111-116.
48. Lemoine NR, Hughes CM, Barton CM, et al. The epidermal growth factor receptor in human pancreatic cancer. J Pathol. 1992;166:7-12.
49. Moscatello DK, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995;55:5536-5539.
50. Ng SS, Tsao MS, Nicklee T, et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther. 2002;1:777-783.
51. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267-3279.
52. Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol. 2007;25:4506-4507; author reply 4508.
53. Boeck S, Vehling-Kaiser U, Waldschmidt D, et al. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'. Anticancer Drugs. 2010;21:94-100.
54. Hammel P, et al. Randomized multicenter phase III study in patients with locally advanced adenocarcinoma of the pancreas: gemcitabine with or without chemoradiotherapy and with or without erlotinib-LAP 07 study. J Clin Oncol. 2011;29:e14619.
55. Overholser JP, Prewett MC, Hooper AT, et al. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer. 2000;89:74-82.
56. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 2000;6:1936-1948.
57. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2004;22:2610-2616.
58. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gem-citabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology GroupYdirected inter-group trial S0205. J Clin Oncol. 2010;28:3605-3610.
59. Arnoletti JP, Frolov A, Eloubeidi M, et al. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 2011;67:891-897.
60. Rosa R, Melisi D, Damiano V, et al. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clin Cancer Res. 2011;17:6531-6541.
61. Hewish M, Chau I, Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov. 2009;4:54-72.
62. Bergmann U, Funatomi H, Yokoyama M, et al. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for auto-crine and paracrine roles. Cancer Res. 1995;55:2007-2011.
63. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009;27: 5800-5807.
64. Kindler HL, Richards DA, Garbo LE, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with meta-static pancreatic cancer. Ann Oncol. 2012;103:2834-2842.
65. Moser C, Schachtschneider P, Lang SA, et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer. 2008;44:1577-1586.
66. Mullendore ME, Koorstra JB, Li YM, et al. Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res. 2009;15:2291-2301.
67. Wang Z, Banerjee S, Li Y, et al. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006;66:2778-2784.
68. Mazur PK, Einwachter H, Lee M, et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA. 2010;107: 13438-13443.
69. Krop I, Demuth T, Guthrie T, et al. Phase I pharmacologic and pharma-codynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J Clin Oncol. 2012;30: 2307-2313.
70. Garrett MD, Collins I. Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci. 2011;32:308-316.
71. Zabludoff SD, Deng C, Grondine MR, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 2008;7:2955-2966.
72. Venkatesha VA, Parsels LA, Parsels JD, et al. Sensitization of pancreatic cancer stem cells to gemcitabine by chk1 inhibition. Neoplasia. 2012;14:519-525.
73. Sausville EA. Phase I dose-escalation study of AZD7762 in combination with gemcitabine (gem) in patients (pts) with advanced solid tumors. J Clin Oncol. 2011;29(suppl). Abstract 3058.
74. Parsels LA, Morgan MA, Tanska DM, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther. 2009;8:45-54.
75. Hattori H, Skoulidis F, Russell P, et al. Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor. Mol Cancer Ther. 2011;10:670-678.
76. Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothe-lial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000;88: 2239-2245.
77. Itakura J, Ishiwata T, Shen B, et al. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer. 2000;85:27-34.
78. von Marschall Z, Cramer T, Hocker M, et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology. 2000;119: 1358-1372.
79. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer. 2003;2:8.
80. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. 2002; 62:1996-2003.
81. Solorzano CC, Baker CH, Bruns CJ, et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm. 2001;16: 359-370.
82. Bockhorn M, Tsuzuki Y, Xu L, et al. Differential vascular and tran-scriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin Cancer Res. 2003;9:4221-4226.
83. Bayraktar S, Rocha-Lima CM. Advanced or metastatic pancreatic cancer: molecular targeted therapies. Mt Sinai J Med. 2010;77:606-619.
84. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:8033-8040.
85. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevaci-zumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the cancer and leukemia group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622.
86. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bev-acizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27:2231-2237.
87. Isacoff W, et al. Metronomic therapy with 5-FU, weekly nab-paclitaxel, leucovorin, and oxaliplatin, plus bevacizumab for advanced pancreatic cancer: a phase II study. J Clin Oncol. 2012;30(suppl):e14582.
88. Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006;5:835-844.
89. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogene-sis. Cancer Res. 2004;64:7099-7109.
90. Ulivi P, Arienti C, Amadori D, et al. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines. J Cell Physiol. 2009;220:214-221.
91. Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res. 2006;12:144-151.
92. El-Khoueiry AB, Ramanathan RK, Yang DY, et al. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest New Drugs. 2012;30:1175-1183.
93. Aparicio J. A phase I dose-finding study of sorafenib (S) in combination with gemcitabine (G) and radiotherapy (RT) in patients (pts) with unresectable pancreatic carcinoma (UPC): a GEMCAD study. J Clin Oncol. 2011;29(suppl). Abstract e14525.
94. Hu-Lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogen-esis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 2008;14:7272-7283.
95. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangio-genesis agent AG-013736 in patients with advanced solid tumors: phar-macokinetic and clinical results. J Clin Oncol. 2005;23:5474-5483.
96. Spano JP, Chodkiewicz C, Maurel J, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008;371:2101-2108.
97. Spano JP, Moore MJ, Pithavala YK, et al. Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. Invest New Drugs. 2012;30:1531-1539.
98. Kindler HL, Ioka T, Richel DJ, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adeno-carcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011;12:256-262.
99. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol. 2008;26:3743-3748.
100. Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and bio-markers of neoadjuvant bevacizumab, radiation therapy, and fluoroura-cil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009; 27:3020-3026.
101. Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev. 2012;38:484-493.
102. Tew WP, Gordon M, Murren J, et al. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res. 2010;16:358-366.
103. Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 2010;28:207-214.
104. Riess H, et al. Double-blind, placebo-controlled randomized phase III trial of aflibercept (A) plus gemcitabine (G) versus placebo (P) plus gemcitabine (G) in patients with metastatic pancreatic cancer: final results. Presented at the 12th World Congress on Gastrointestinal Cancer 2010, Barcelona, Spain.
105. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res. 1999;5:2018-2024.
106. Molina MA, Sitja-Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999;59:4356-4362.
107. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999; 59:987-990.
108. El-Rayes BF, Ali S, Sarkar FH, et al. Cyclooxygenase-2Ydependent and Yindependent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther. 2004;3:1421-1426.
109. Xiong HQ, Plunkett W, Wolff R, et al. A pharmacological study of cel-ecoxib and gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2005;55:559-564.
110. Lipton A, Campbell-Baird C, Witters L, et al. Phase II trial of gemci-tabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. J Clin Gastroenterol. 2010;44:286-288.
111. El-Rayes BF, Zalupski MM, Shields AF, et al. A phase II study of cel-ecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs. 2005;23:583-590.
112. Ferrari V, Valcamonico F, Amoroso V, et al. Gemcitabine plus cele-coxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol. 2006;57:185-190.
113. Cottam D, Rees R. Regulation of matrix metalloproteinasesVtheir role in tumor invasion and metastasis. Int J Oncol. 1993;2:861-872.
114. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol. 1995;6:967-974.
115. Steward WP. Marimastat (BB2516): current status of development. Cancer Chemother Pharmacol. 1999;43(suppl):S56-S60.
116. Rosemurgy A, Harris J, Langleben A, et al. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol. 1999;2:247-252.
117. Nemunaitis J, Poole C, Primrose J, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res. 1998;4:1101-1109.
118. Evans JD, Stark A, Johnson CD, et al. A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer. 2001;85:1865-1870.
119. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002;87:161-167.
120. Hirte H, Goel R, Major P, et al. A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Ann Oncol. 2000;11:1579-1584.
121. Erlichman C, Adjei AA, Alberts SR, et al. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann Oncol. 2001;12:389-395.
122. Heath EI, O'Reilly S, Humphrey R, et al. Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2001;48:269-274.
123. Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pa: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21:3296-3302.
124. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003;425: 851-856.
125. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature. 2003;425:846-851.
126. Bailey JM, Swanson BJ, Hamada T, et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res. 2008;14:5995-6004.
127. Yauch RL, Gould SE, Scales SJ, et al. A paracrine requirement for hedgehog signalling in cancer. Nature. 2008;455:406-410.
128. Feldmann G, Dhara S, Fendrich V, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007;67:2 187-2196.
129. Chenna V, Hu C, Pramanik D, et al. A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists. Mol Cancer Ther. 2012;11:165-173.
130. Onishi H, Morifuji Y, Kai M, et al. Hedgehog inhibitor decreases che-mosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer. Cancer Sci. 2012;103:1272-1279.
131. Tremblay MR, Lescarbeau A, Grogan MJ, et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem. 2009;52:4400-4418.
132. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457-1461.
133. Nolan-Stevaux O, Lau J, Truitt ML, et al. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009;23:24-36.
134. Richards D, et al. A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer. J Clin Oncol. 2012;30(suppl 4). Abstract 213.
135. Ko A, et al. A phase Ib trial of FOLFIRINOX plus saridegib, an oral hedgehog (Hh) inhibitor, in pts with advanced pancreatic cancer (PDAC). J Clin Oncol. 2012;30(suppl). Abstract 3105.
136. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583-592.
137. Thompson CB, Shepard HM, O'Connor PM, et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol Cancer Ther. 2010;9:3052-3064.
138. Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal ade-nocarcinoma. Cancer Cell. 2012;21:418-429.
139. Shepard HM, et al. Targeting hyaluronan (HA) in the tumor stroma: translational evaluation of pegylated hyaluronidase (PEGPH20) in animal models and patients with advanced solid tumors. Presented at the European Organisation for Research and Treatment of Cancer 2010, Florida.
140. Infante JR, et al. Targeting hyaluronan (HA) in tumor stroma: interim safety and translational evaluation of pegylated hyaluronidase (PEG-PH20) in patients (pts) with advanced solid tumors: a focus on gastrointestinal malignancies. J Clin Oncol. 2012;30(suppl 4). Abstract 249.
141. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overex-pressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862-3868.
142. Hassan R, Laszik ZG, Lerner M, et al. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol. 2005;124:838-845.
143. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a re-combinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007;13:5144-5149.
144. Kreitman RJ, Hassan R, Fitzgerald DJ, et al. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009;15:5274-5279.
145. Hassan R, Ebel W, Routhier EL, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 2007;7:20.
146. Hassan R, Cohen SJ, Phillips M, et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res. 2010;16:6132-6138.
147. Roy LD, Sahraei M, Subramani DB, et al. MUC1 enhances invasive-ness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene. 2011;30:1449-1459.
148. Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother. 2005;54:254-264.
149. Rong Y, Qin X, Jin D, et al. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Clin Exp Med. 2012;12:173-180.
150. Lepisto AJ, Moser AJ, Zeh H, et al. A phase I/II study of a MUC1 pep-tide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008; 6:955-964.
151. Smith JP, Fantaskey AP, Liu G, et al. Identification of gastrin as a growth peptide in human pancreatic cancer. Am J Physiol. 1995;268: R135-R141.
152. Caplin M, Savage K, Khan K, et al. Expression and processing of gas-trin in pancreatic adenocarcinoma. Br J Surg. 2000;87:1035-1040.
153. Gilliam AD, Watson SA. G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther. 2007; 7:397-404.
154. Brett BT, Smith SC, Bouvier CV, et al. Phase II study of antiYgastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol. 2002;20:4225-4231.
155. Shapiro J, et al. G17DT+gemcitabine(Gem) versus placebo + Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: results of randomized, double-blind, multinational, multicenter study. J Clin Oncol. 2005;23(a4012).
156. Gilliam AD, Broome P, Topuzov EG, et al. An international multi-center randomized controlled trial of G17DT in patients with pancreatic cancer. Pancreas. 2012;41:374-379.
157. Chau I, Cunningham D, Russell C, et al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006;94:1107-1115.
158. Nomi T, Sho M, Akahori T, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13:2151-2157.
159. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19:813-824.
160. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167-3175.
161. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
162. Qu CF, Li Y, Song YJ, et al. MUC1 expression in primary and meta-static pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate. Br J Cancer. 2004;91:2086-2093.
163. Dang T, et al. The role of Notch3 signaling pathway in pancreatic cancer. J Clin Oncol. 2007;25(suppl). Abstract 21049.
164. Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res. 1993;13: 565-569.
165. Bloomston M, Bhardwaj A, Ellison EC, et al. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig Surg. 2006;23:74-79.
166. Hakam A, Fang Q, Karl R, et al. Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Dig Dis Sci. 2003; 48:1972-1978.